Technical Analysis for GNLX - Genelux Corporation

Grade Last Price % Change Price Change
F 6.72 0.67% 0.05
GNLX closed down 3.05 percent on Friday, February 23, 2024, on 2.13 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Feb 28
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.67%
Spinning Top Other 0.67%
New 52 Week Low Weakness 0.67%
Wide Bands Range Expansion 0.67%
Down 3 Days in a Row Weakness 0.67%
Down 4 Days in a Row Weakness 0.67%
Down 5 Days in a Row Weakness 0.67%
Oversold Stochastic Weakness 0.67%
New 52 Week Closing Low Bearish -2.40%
Reversal New Lows Setup Bearish Swing Setup -2.40%

   Recent Intraday Alerts

Alert Time
Down 2 % 35 minutes ago
Down 1% 35 minutes ago
Up 1% 35 minutes ago
Up 3% 3 days ago
Up 2% 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Treatment Of Ovarian Cancer Experimental Cancer Treatments Transgene Sa Treatment Of Pancreatic Cancer

Is GNLX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 40.98
52 Week Low 6.4
Average Volume 124,872
200-Day Moving Average 20.29
50-Day Moving Average 11.56
20-Day Moving Average 8.84
10-Day Moving Average 7.87
Average True Range 0.92
RSI (14) 24.81
ADX 23.78
+DI 11.27
-DI 29.70
Chandelier Exit (Long, 3 ATRs) 9.35
Chandelier Exit (Short, 3 ATRs) 9.17
Upper Bollinger Bands 11.43
Lower Bollinger Band 6.24
Percent B (%b) 0.08
BandWidth 58.74
MACD Line -1.30
MACD Signal Line -1.21
MACD Histogram -0.0936
Fundamentals Value
Market Cap 178.21 Million
Num Shares 26.7 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -6.29
Price-to-Sales 1003.60
Price-to-Book 10.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.77
Resistance 3 (R3) 7.80 7.46 7.58
Resistance 2 (R2) 7.46 7.18 7.45 7.52
Resistance 1 (R1) 7.07 7.01 6.90 7.04 7.46
Pivot Point 6.73 6.73 6.65 6.72 6.73
Support 1 (S1) 6.34 6.45 6.17 6.31 5.88
Support 2 (S2) 6.00 6.28 5.99 5.82
Support 3 (S3) 5.61 6.00 5.76
Support 4 (S4) 5.58